CNBC January 14, 2024
Annika Kim Constantino

Key Points

– An established but promising group of cancer drugs was a red-hot market in 2023, and more acquisitions and advancements are expected in the year ahead.

– That was one clear takeaway from the JPMorgan Healthcare Conference in San Francisco.

– Researchers say those drugs could have less toxicity – or unwanted effects on your body that could lead to harm – than standard chemotherapy.

SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead.

That was one clear takeaway from the JPMorgan Healthcare Conference in San Francisco, the nation’s largest gathering of biotech and pharmaceutical...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Pharma, Pharma / Biotech, Trends
Drugmakers counter HHS' first offers in Medicare price talks
Pfizer stops buildout of $350M Seagen plant, leaving 120 workers' roles in question
Walgreens CEO: Shields Specialty Pharmacy Key To Growth And Won’t Be Sold
ARPA-H behind on duplicative research efforts, GAO says
Retail pharmacies to begin selling OTC birth control within weeks

Share This Article